The agreement is intended for the manufacture and sale of three anti-ageing products specifically formulated by Phosphagenics for the Indian market.
Under the deal, Intas will pay an undisclosed royalty and will market the new products, incorporating Phosphagenics’ patented Targeted Penetration Matrix (TPM) technology across India.
Phosphagenics CEO Esra Ogru said the company is expected to launch a full dermatological line of personal care products in India if the first three products are a success.
TPM is a patented topical and transdermal delivery technology which enables superior delivery of various active ingredients into or through the skin.